The goal of this clinical trial is to learn whether teduglutide, a medicine that helps the intestine heal, can improve environmental enteric dysfunction in undernourished women aged 18 to 35 years living in urban slums of Dhaka.
Environmental enteric dysfunction is a long-lasting condition of the small intestine. It causes inflammation and poor absorption of nutrients. Many people with this condition do not have clear symptoms, but it can make undernutrition worse. At present, there is no proven treatment for this condition.
The main questions this study aims to answer are:
* Does taking teduglutide for 30 days improve damage to the small intestine, as seen on intestinal biopsy?
* Does teduglutide improve blood and stool markers related to gut inflammation and nutrient absorption?
Participants will:
* Receive nutritional support at the start of the study
* Undergo an upper gastrointestinal endoscopy to confirm environmental enteric dysfunction
* Receive a daily injection of teduglutide under the skin for 30 days
* Undergo repeat endoscopy and laboratory tests after treatment to assess changes in gut health The results of this study will help researchers understand whether teduglutide may be a useful treatment for environmental enteric dysfunction in undernourished adult women and will guide future, larger studies.

Start Date01 Jul 2026

Sponsor / Collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

NCT06973304

/ Active, not recruitingPhase 3

An Open-label, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of 0.05 mg/kg/Day Subcutaneous Teduglutide Following Treatment of Short Bowel Syndrome for 24 Weeks in Chinese Adults Who Are Dependent on Parenteral Support

The main aim of the study is to assess how well teduglutide works over 24 weeks in Chinese adult participants with short bowel syndrome (SBS) who need parenteral support and to see how much it can reduce the amount of parenteral support and understand how the body absorbs, processes, and gets rid of teduglutide.
Participants will receive a daily injection of teduglutide under the skin for 24 weeks. Safety of teduglutide will be checked for 24 weeks after treatment.
Participants will be in the study for about 65 weeks.

Start Date26 Jun 2025

Sponsor / Collaborator

Takeda Pharmaceutical Co., Ltd.

ChiCTR2500095623

/ Not yet recruitingPhase 4IIT

Efficacy of Teduglutide in the treatment of acute myocardial infarction: a prospective single-center randomized controlled study

Start Date01 Jan 2025

Sponsor / Collaborator

Anhui Medical University No. 1 Affiliated Hospital

100 Clinical Results associated with Teduglutide Recombinant

100 Translational Medicine associated with Teduglutide Recombinant

100 Patents (Medical) associated with Teduglutide Recombinant

306

Literatures (Medical) associated with Teduglutide Recombinant

01 Jan 2027·TALANTA

Development of Teduglutide purity certified reference material (GBW09342) through amino acid-based isotope dilution mass spectrometry and sulfur-based isotope dilution inductively coupled plasma mass spectrometry

Article

Author: Feng, Liuxing ; Wei, Yun ; Zhou, Xirui ; Wu, Peize ; Li, Na

As a severe intestinal disorder, short bowel syndrome (SBS) has become the leading cause of chronic intestinal failure worldwide. Teduglutide, a 33-amino-acid glucagon-like peptide-2 (GLP-2) analog, offers a novel therapeutic option for individuals suffering from SBS. In this study, Teduglutide purity certified reference material (CRM) with certified value and expanded uncertainty of (85.0% ± 2.7%) was developed with Teduglutide produced through recombinant gene expression technique. After a comprehensive purity verification and structure confirmation, two independent isotope dilution mass spectrometry (IDMS) strategies based on amino acid (AA) and sulfur measurements were employed for CRM certification, with the later strategy being used for the first time to certify a solid purity CRM. The Teduglutide purity CRM showed good homogeneity, it also exhibited satisfying stability for at least 14 days at 4 °C, 24 h for 25 °C and 12 months at -20 °C. The development of Teduglutide purity CRM (GBW09342) enables the establishment of accurate and reliable analytical methods for purity assessment, which is essential for ensuring the quality, consistency, and clinical safety of corresponding pharmaceutical products. It also provides a reliable reference for the quality control of other peptide-related drugs.

01 Oct 2026·Clinical Nutrition ESPEN

Association between teduglutide treatment and long-term reductions in parenteral support: An observational cohort study of adults with short bowel syndrome

Article

Author: Raman, Maitreyi ; Allard, Johane P ; Gramlich, Leah ; Daoud, Dane C ; Jin, Jennifer ; Demchyshyn, Lidia ; Nguyen, Michelle M L ; Chen, Johnny H ; Weiss, Jessica

BACKGROUND:

Teduglutide is indicated for the treatment of patients with short bowel syndrome with intestinal failure (SBS-IF) who are dependent on parenteral support.

AIM:

This study aimed to evaluate the association between teduglutide treatment and changes in parenteral support requirements in adult patients with SBS-IF in a real-world setting.

METHODS:

This study was an observational, retrospective study of adult patients with SBS-IF receiving teduglutide as per standard of care and participating in the National Canadian Takeda OnePath Patient Support Program. Baseline and follow-up clinical data that included adverse events were collected between December 1, 2014 and December 1, 2023. Analyses were descriptive and results are presented as medians with interquartile ranges and proportions.

RESULTS:

Fifty-two patients were included (59.6% women; median age 54.0 years). Crohn's disease was the underlying etiology in 50.0% of patients. Median baseline weekly parenteral support volume was 11,600.0 mL/week. At 6 months, median absolute reduction from baseline in parenteral support volume was 3900.0 mL/week. At 24 months, median absolute reduction from baseline was 6650.0 mL/week, and the proportion of patients who achieved ≥20% reduction in weekly parenteral support volume was 66.7%. Over the study period, 26.9% achieved independence from parenteral support. The most common adverse events were weight changes, diarrhea, and fatigue.

CONCLUSION:

In real-world practice, teduglutide treatment was associated with lower parenteral support volumes in adult patients with SBS-IF, with 26.9% of patients achieving independence from parenteral support. No adverse events outside the known safety profile of teduglutide were identified, and findings were consistent with previously reported clinical trial and real-world studies.

01 Aug 2026·Clinical Nutrition ESPEN

Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure

Article

Author: Beck, Kendall R ; Ziegler, Thomas R ; Chen, Lily ; Greatsinger, Ali ; Byers, Patricia M ; Binion, David G ; Cheng, Mu ; Gao, Emily ; Kang, Zoey ; Swallow, Elyse ; Jiang, Jeanne ; Kim, Dong Wook ; Zhao, Vivian M ; Pham, Angela K

BACKGROUND & AIMS:

Patients with short bowel syndrome-associated intestinal failure (SBS-IF) require parenteral nutrition and/or intravenous fluids (PN/IV); however, long-term dependence can lead to complications. Teduglutide enhances mucosal growth and the absorptive function of the residual intestine and reduces dependence on PN/IV. We aimed to investigate the use of teduglutide in real-world settings.

METHODS:

This retrospective study assessed outcomes in adult patients with SBS-IF who had received teduglutide (ever-treated cohort) or were eligible for teduglutide but had never received it (never-treated cohort). De-identified medical record data between December 21, 2011 and March 1, 2023 were abstracted from patient charts at US-based centers. Outcomes were analyzed using descriptive statistics and Kaplan-Meier methods.

RESULTS:

Age, presence of a stoma, time since SBS-IF diagnosis, and PN/IV frequency significantly differed between the ever-treated (n = 103) and never-treated cohorts (n = 121) at baseline. During follow-up, ever-treated (mean duration, 19.4 months) and never-treated patients (mean duration, 19.1 months) had similar reductions from baseline in PN/IV days per week (mean [standard deviation] change: -0.9 [2.1] vs -1.0 [2.8] days) and PN/IV volume (-1.7 [3.6] vs -2.0 [6.2] L/week). Mean (SD) change in PN/IV energy received during follow-up was -1110.4 [3158.2] kcal/week for ever-treated patients and -408.3 [2836.2] kcal/week for never-treated patients. Clinical response and enteral autonomy were attained by 62.9 % and 20.2 % of ever-treated patients and 55.9 % and 27.9 % of never-treated patients, respectively. In ever-treated patients, 71.8 % experienced a treatment delay, 35.0 % discontinued teduglutide treatment, and 16.5 % experienced a treatment interruption.

CONCLUSION:

In this real-world US multicenter chart review study, PN/IV dependency reduced in patients with SBS-IF receiving or not receiving teduglutide. Heterogeneity in patient characteristics and treatment delays, discontinuations, and interruptions may have impacted the effectiveness of teduglutide. These results will inform healthcare professionals of the current practices and typical outcomes associated with teduglutide treatment.

News (Medical) associated with Teduglutide Recombinant

06 Jun 2026

·www.biospace.com

Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate

Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome. Eli Lilly’s late-spring dealmaking spree shows no sign of stopping as the pharma giant stuck a licensing agreement with South Korean biotech Hanmi Pharm worth up to $1.2 billion for access to a potential next wave of metabolic drugs. Under the deal, Lilly will help develop Hanmi’s Phase 2 GLP-2 agonist sonefpeglutide with exclusive rights to manufacture and sell the therapy everywhere except Korea. Hanmi plans to complete the ongoing mid-stage study in short bowel syndrome while Lilly will “explore additional clinical trials for sonefpeglutide” based on existing data, according to a press release. The deal includes an upfront payment of $75 million with the rest of the $1.2 billion subject to the achievement of certain milestones. A rare disease that affects newborns as well as adults who have undergone gastrointestinal surgery, short bowel syndrome limits the absorption of nutrients in a shortened or damaged small intestine. Hanmi’s GLP-2 sonefpeglutide is designed to promote intestinal growth, reduce inflammation, and protect and regenerate the intestinal mucosa. If sonefpeglutide eventually reaches the market, it wouldn’t be the first GLP-2 to do so, owing to the 2012 approval of Takeda’s Gattex, also for short bowel syndrome. Zealand Pharma also attempted to break into the space, only for its GLP-2 candidate glepaglutide to be rejected by the FDA in 2024. Hanmi credits its protein and peptide discovery platform Lapscovery for sonefpeglutide’s progress. The company has used the platform to develop the white blood cell booster Rolvedon that was approved in 2022 and has five other clinical programs making use of the technology. Lilly, which leads the GLP-1 weight loss space with blockbusters Zepbound and Mounjaro plus recently approved oral Foundayo and the standout investigational triple-agonist retatrutide, has expanded into gastrointestinal indications like Crohn’s disease and ulcerative colitis. The Hanmi deal marks another step in that direction with sights set on short bowel syndrome. Swimming in weight loss drug earnings, the U.S. pharma giant has been on the hunt for pipeline candidates across a wide range of therapeutic areas, as witnessed through a series of deals over the course of the last few months. A trilogy of vaccine agreements in May added up to a combined value of $3.8 billion. And the company has struck no fewer than five oncology deals so far this year, reflecting an R&D–focused growth mindset and an urge to bring a new generation of treatments to the market. “It is highly meaningful that Lilly—one of the most closely watched innovators globally—has recognized the development potential for sonefpeglutide,” Hanmi Vice Chairman Jhuyun Lim said in a statement. The content above comes from the network. if any infringement, please contact us to modify.

License out/inDrug ApprovalVaccine

01 Jun 2026

·allsci.com

Lilly licenses Hanmi’s GLP-2 agonist sonefpeglutide in USD 1.26b deal

Eli Lilly (NYSE: LLY) has agreed to pay USD 75 million upfront to license sonefpeglutide, a long-acting GLP-2 receptor agonist biologic, from South Korean drugmaker Hanmi Pharm. Co., Ltd. (KRX: 128940), in a pharmaceutical licensing agreement that could total up to USD 1.26 billion including milestones. The deal grants Lilly exclusive worldwide rights — excluding South Korea — to develop, manufacture, and commercialize the LAPSGLP-2 analog across multiple indications, with Hanmi retaining rights to complete its ongoing global Phase II trial in short bowel syndrome (SBS). Under the agreement, Hanmi is eligible to receive up to USD 1.185 billion in clinical development, regulatory approval, and commercialization milestone payments, in addition to sales-based royalties following product launch. Specific milestone amounts and royalty rates were not disclosed. Deal context Sonefpeglutide is a PEGylated GLP-2 receptor agonist engineered using Hanmi’s proprietary LAPSCOVERY platform, which extends the circulating half-life of peptides and proteins through site-specific conjugation to an aglycosylated immunoglobulin Fc fragment via a non-peptidyl polymer linker. The architecture exploits FcRn-mediated endosomal recycling — the same mechanism that gives IgG antibodies their roughly 21-day half-life — while the aglycosylated Fc eliminates effector functions that would be inappropriate for a non-antibody therapeutic context. GLP-2, the native hormone that sonefpeglutide mimics, has a circulating half-life of approximately seven minutes, making unmodified peptide therapeutics clinically impractical at meaningful dosing intervals. The approved GLP-2 analog teduglutide (Gattex, Takeda) requires daily subcutaneous injection; sonefpeglutide’s extended half-life is designed to enable once-weekly or less frequent dosing, which would represent a meaningful improvement in patient convenience if borne out in Phase III data. GLP-2 receptor activation promotes intestinal mucosal growth, reduces inflammation, and supports repair and regeneration of the intestinal lining — mechanisms with established relevance to SBS, a rare condition in which patients lose absorptive capacity following surgical removal of large portions of the small intestine and often require long-term parenteral nutrition. Hanmi is currently conducting a global Phase II trial in SBS and will complete that study independently; Lilly will lead any additional clinical programs it elects to pursue based on the available nonclinical and clinical data package. Beyond SBS, the press release indicates Lilly intends to explore additional indications, though none were named. The LAPSCOVERY platform has previously generated clinical-stage assets in adjacent metabolic areas — including efpeglenatide, a GLP-1 analog that Hanmi previously licensed to Sanofi and which completed a Phase III cardiovascular outcomes trial, albeit Sanofi pulled out of that molecule’s development in 2020. The deal is the latest in a sequence of licensing agreements Lilly has signed with biotech companies over the past 18 months, reflecting a sustained effort to source external assets across modalities. In May 2025, Lilly signed a USD 415 million licensing agreement with Alchemab Therapeutics for ATLX-1282, a first-in-class neurodegenerative candidate. That same month, South Korea-based Rznomics entered a global licensing agreement with Lilly for RNA-editing therapeutics, and in January 2026, Seamless Therapeutics announced a global research collaboration with Lilly focused on programmable recombinase-based gene therapies for hearing loss. For Lilly, the transaction adds a gastrointestinal rare disease asset to a portfolio historically concentrated in diabetes and obesity. The GLP-2 receptor mechanism is biologically distinct from GLP-1 — sonefpeglutide does not carry the weight-loss or glycemic control profile of Lilly’s tirzepatide franchise — but the intestinotrophic biology has potential applicability beyond SBS to other conditions involving intestinal barrier dysfunction, a space that has attracted increasing clinical interest. Whether Lilly pursues those broader indications will depend on the Phase II SBS data Hanmi is generating, the full package of which Lilly will inherit upon trial completion. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.

05 May 2026

·www.biospace.com

British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome

TORONTO , May 5, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") announced that REVESTIVE ® (teduglutide for injection) will now be reimbursed by BC PharmaCare for eligible pediatric and adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. 1 Coverage is subject to specific criteria. 2 For people living with SBS, reimbursed access can help reduce reliance on parenteral support, which includes intravenous administration of nutrition, fluids, and electrolytes. "We welcome the Government of B.C.'s decision to reimburse REVESTIVE for people living with Short Bowel Syndrome. This decision is an important step toward improving equitable access to care and supporting better health outcomes," said Gail Attara, CEO and Co-founder of the Gastrointestinal Society and President of the Canadian Society of Intestinal Research. "Patient organizations have long engaged with provincial governments on the need for timely access to therapies for rare digestive disorders. We look forward to continuing to work collaboratively with policymakers and partners to strengthen access to appropriate treatments for Canadians living with complex GI conditions." SBS occurs when the small intestine is unable to absorb enough nutrients and fluids – often due to surgical removal, damage, or disease. 3 People living with SBS may experience dehydration, malnutrition, fatigue, and weight loss, among other serious health impacts. 3 Management can include medications, surgery, and significant dietary changes. 4 SBS affects approximately 800 Canadians and has an estimated mortality rate of almost 40 per cent. 5 "Many people living with SBS rely on parenteral support delivered intravenously (IV). While lifesaving, IV support can be associated with serious complications and can significantly affect quality of life for patients and caregivers," said Dr. Andrea Martinez, Medical Director, Complex Feeding and Nutrition Service, BC Children's Hospital. "REVESTIVE has been shown to help some patients reduce their need for parenteral support, which can translate into meaningful improvements not only in day-to-day life but also in long-term outcomes." Health Canada issued a Notice of Compliance for REVESTIVE in 2015 for the treatment of adult patients with SBS who are dependent on parenteral support. It was approved in Canada for pediatric patients one year of age and above for the same indication in 2019. "This reimbursement is another step forward for people in B.C. living with Short Bowel Syndrome, improving access to a therapy that can help eligible patients reduce reliance on parenteral support," said Thiago Magalhães, Business Unit Head, GI² and Mature Brands. "REVESTIVE reflects Canadian innovation, rooted in the discovery of Glucagon-like peptide-2 (GLP-2) at the University of Toronto and advanced through Canadian research, development, and clinical participation." About REVESTIVE ® REVESTIVE ® (teduglutide for injection) is currently indicated in Canada for the treatment of adults and pediatric patients one year of age and above with Short Bowel Syndrome who are dependent on parenteral support. 1 About Short Bowel Syndrome with Intestinal Failure Short bowel syndrome–associated intestinal failure (SBS-IF) is characterized by reduced gut absorptive function below the minimum necessary for absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation (parenteral nutrition and/or IV fluids/electrolytes) is required to maintain health. When intestinal adaptation is inadequate following extensive intestinal resection or injury, patients may require chronic parenteral support to maintain hydration and nutrient balance. 6 , 7 , 8 About Takeda Canada Inc. Takeda Canada Inc. is the Canadian organization of Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) , a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit: . _______________________________________ 1 REVESTIVE (Teduglutide for injection), Submission Control 296120, Product Monograph, Takeda Canada Inc. (SEP 19, 2025). Available at: . 2 Drug Coverage Decision for BC PharmaCare. Available at: (accessed April 2026). 3 GI Society, Canadian Society of Intestinal Research. Short Bowel Syndrome. Available at: Short Bowel Syndrome | Gastrointestinal Society . 4 O'Keefe SJD, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. (2006). Short bowel syndrome and intestinal failure: Consensus definitions and overview. Clin Gastroenterol Hepatol; 4:6-10. 5 Amin S, Pappas C, Lyengar H, Maheshwari A. Short Bowel Syndrome in the Nicu. Clin Perinatol. 2013 Jan 17;40(1):10.1016/j.clp.2012.12.003. doi: 10.1016/j.clp.2012.12.003. PMID: 23415263; PMCID: PMC3886240. Available at: Short Bowel Syndrome in the Nicu - PMC . 6 Pironi L, et al. ESPEN guideline on chronic intestinal failure in adults – Update 2023. Clinical Nutrition. 2023 Oct;42(10):1940–2021. doi:10.1016/j.clnu.2023.07.019. PMID: 37639741. (guidelinecentral.com). 7 Wauters L, Joly F. Treatment of short bowel syndrome: Breaking the therapeutic ceiling? Nutr Clin Pract. 2023 May;38(Suppl 1):S76–S87. doi:10.1002/ncp.10974. PMID: 37115030. (pubmed.ncbi.nlm.nih.gov). 8 Bering J, DiBaise JK. Short Bowel Syndrome in Adults. Am J Gastroenterol. 2022 Jun 1;117(6):876–883. doi:10.14309/ajg.0000000000001763. PMID: 35383576. (pubmed.ncbi.nlm.nih.gov). SOURCE Takeda Canada Inc.

100 Deals associated with Teduglutide Recombinant

External Link

KEGG	Wiki	ATC	Drug Bank
-	Teduglutide Recombinant	A16AX08	DB08900

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Short Bowel Syndrome	European Union	Takeda Pharmaceuticals International AG	30 Aug 2012
Short Bowel Syndrome	Iceland	Takeda Pharmaceuticals International AG	30 Aug 2012
Short Bowel Syndrome	Liechtenstein	Takeda Pharmaceuticals International AG	30 Aug 2012
Short Bowel Syndrome	Norway	Takeda Pharmaceuticals International AG	30 Aug 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Postoperative Complications	Phase 3	United States	Shire Plc	02 Jun 2022
Fistula	Phase 2	United States	Takeda Pharmaceutical Co., Ltd.	31 Jan 2019
Crohn Disease	Phase 2	United States	Shire Plc	12 Nov 2003
Crohn Disease	Phase 2	Canada	Shire Plc	12 Nov 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02954458 \| NCT02949362 (Pubmed \| J Pediatr Gastroenterol Nutr)	Phase 3	Intestinal Failure	69	Teduglutide (short bowel syndrome-associated intestinal failure)	xkxgevdxhc(gzbmyxtqaz) = ladnkqxmha jjazimmiuw (tzjwkttcxv )	Positive	01 Jul 2026
ECCO2025	Not Applicable	Short Bowel Syndrome	10	Teduglutide	vnqhopsvep(zompkrmsrt) = dwirpanbbz wmmugnfrsp (gesjdlpyne ) View more	Positive	19 Feb 2025
UEGW2024	Not Applicable	syndrome; salt-losing, adrenogenital syndrome	-	TEDUGLUTIDE	tdslkyzgmi(kzfhamifhu) = qmjamdpuju mowufotjdk (ouhihncpgs )	-	13 Oct 2024
UEGW2024	Not Applicable	Intestinal Failure	-	TEDUGLUTIDE	joydrddefo(ferluoorvx) = wsllmnkauy bllwhxaxol (voludvrzau ) View more	-	13 Oct 2024
UEGW2024	Not Applicable	Intestinal Failure	-	Placebo	joydrddefo(ferluoorvx) = fnhlltpkza bllwhxaxol (voludvrzau ) View more	-	13 Oct 2024
NCT02954458 \| NCT02949362 (Pubmed \| J Pediatr Gastroenterol Nutr)	Phase 3	Intestinal Failure	85	Teduglutide	lasfvrtydc(iedjmighba) = wealksgyvi uapetrcvdx (hbwvehnatz )	Positive	01 Aug 2024
NCT05027308 (CTgov)	Phase 3	Short Bowel Syndrome	3	Teduglutide	ullcmsgvsf = olbuyerjdq ldjnjqparq (fxcpaiypwk, asqknyljqj - mfsoywbliz) View more	-	16 May 2024
NCT02682381 \| NCT01952080 (SBS-IF, Pubmed \| J Pediatr Gastroenterol Nutr)	Phase 3	Intestinal Failure	101	Teduglutide	opfolnwwvj(mqhatkkbvn) = Safety assessments included gastrointestinal adverse event reporting jxkneuimhd (wbjbhngxep )	Positive	01 Nov 2023
	Phase 3	Intestinal Failure	101	Teduglutide (Standard of care)		Positive	01 Nov 2023
NCT03268811 \| NCT03571516 \| NCT02980666 (Pubmed)	Phase 3	Short Bowel Syndrome	-	Teduglutide	prgyrqphyy(egvzgpzwoe) = All adverse events were in line with known impacts of SBS-IF and adverse reactions to teduglutide. Only one serious adverse event (abdominal pain) was considered related to teduglutide. dysxvmcnzp (wqkqghavsp )	Positive	27 Jun 2023
NCT03268811 \| NCT03571516 \| NCT02980666 (Pubmed)	Phase 3	Short Bowel Syndrome	-	Teduglutide (Standard of care)		Positive	27 Jun 2023
NCT02431325 (CTgov)	Phase 2	Arteritis \| HIV Infections	32	Teduglutide (Teduglutide)	sfvkbeugbu(pisteajilz) = ypdtxsohqo cxawqxetaf (mqtmypxvts, 0.29) View more	-	12 Jun 2023
NCT02431325 (CTgov)	Phase 2	Arteritis \| HIV Infections	32	Placebo (Placebo)	sfvkbeugbu(pisteajilz) = zfrnoulnzl cxawqxetaf (mqtmypxvts, 0.35) View more	-	12 Jun 2023
NCT03562130 (Pubmed \| Am J Clin Nutr)	Phase 4	Short Bowel Syndrome	25	Teduglutide	sbdcydjlgj(wpnhauhxsb) = Mild abdominal pain at the early phase of treatment, stoma changes, and redness at the injection site were commonly reported opspzsphkd (amqjdahntr )	-	01 Jun 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis